Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052832 · ClinicalTrials.gov registry record · Phase 2
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
A Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00052832: Completed Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by University of Wisconsin, Madison.
NCT00052832 is a Phase 2 study of Leukemia and Myelodysplastic Syndromes that has completed, run by University of Wisconsin, Madison. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00052832, a Phase 2 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Doxercalciferol may improve low blood cell counts and decrease the need for blood transfusions and may be an effective treatment for myelodysplastic syndrome or chronic myelomonocytic leukemia. PURPOSE: Phase II trial to study the effectiveness of doxercalciferol in treating patients who have myelodysplastic syndrome or chronic myelomonocytic leukemia.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT doxercalciferol
Study Locations (1)
Wisconsin
- University of Wisconsin Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Phase | Phase 2 |
What the finished NCT00052832 record still lists
NCT00052832 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 3 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which doxercalciferol is the first listed.
NCT00052832 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00052832 about?
NCT00052832 is a clinical study titled "Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia". RATIONALE: Doxercalciferol may improve low blood cell counts and decrease the need for blood transfusions and may be an effective treatment for myelodysplastic syndrome or chronic myelomonocytic leukemia. PURPOSE: Phase II trial to study the effectiveness of doxercalciferol in treating patients who...
What is the current status of trial NCT00052832?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-09.
What conditions does trial NCT00052832 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases.
What interventions are being tested in trial NCT00052832?
The interventions under investigation include: doxercalciferol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00052832?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00052832 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia